J. Kastelein

1.1k total citations
28 papers, 785 citations indexed

About

J. Kastelein is a scholar working on Surgery, Cancer Research and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, J. Kastelein has authored 28 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 9 papers in Cancer Research and 8 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in J. Kastelein's work include Lipoproteins and Cardiovascular Health (17 papers), Cancer, Lipids, and Metabolism (9 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers). J. Kastelein is often cited by papers focused on Lipoproteins and Cardiovascular Health (17 papers), Cancer, Lipids, and Metabolism (9 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers). J. Kastelein collaborates with scholars based in Netherlands, United States and Australia. J. Kastelein's co-authors include Joep C. Defesche, Eric J.G. Sijbrands, Philip J. Barter, Alistair V.W. Nunn, Richard Hobbs, Marjolein Visser, Geesje M. Dallinga‐Thie, Erik S.G. Stroes, Karim El Harchaoui and Emily Cohen and has published in prestigious journals such as The Lancet, Nature Genetics and Journal of the American College of Cardiology.

In The Last Decade

J. Kastelein

27 papers receiving 758 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Kastelein Netherlands 8 541 312 161 156 106 28 785
Martin P. Bogsrud Norway 20 739 1.4× 241 0.8× 274 1.7× 229 1.5× 118 1.1× 84 1.1k
Robert S. Rosenson United States 13 525 1.0× 368 1.2× 359 2.2× 142 0.9× 129 1.2× 26 961
Adriana Branchi Italy 14 296 0.5× 361 1.2× 173 1.1× 149 1.0× 155 1.5× 40 1000
Amanda J. Berberich Canada 12 463 0.9× 338 1.1× 337 2.1× 165 1.1× 147 1.4× 24 828
Angelique C.M. Jansen Netherlands 11 460 0.9× 245 0.8× 136 0.8× 181 1.2× 53 0.5× 12 644
Paul Ziajka United States 11 1.0k 1.9× 499 1.6× 315 2.0× 271 1.7× 111 1.0× 18 1.3k
Tomáš Štulc Czechia 16 567 1.0× 263 0.8× 198 1.2× 125 0.8× 258 2.4× 58 1.0k
Joost Besseling Netherlands 13 1.1k 2.0× 497 1.6× 259 1.6× 382 2.4× 91 0.9× 26 1.3k
M van Linde-Sibenius Trip Netherlands 8 706 1.3× 480 1.5× 401 2.5× 216 1.4× 116 1.1× 8 1.2k
C.D. Furberg United States 8 338 0.6× 356 1.1× 231 1.4× 108 0.7× 53 0.5× 17 690

Countries citing papers authored by J. Kastelein

Since Specialization
Citations

This map shows the geographic impact of J. Kastelein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Kastelein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Kastelein more than expected).

Fields of papers citing papers by J. Kastelein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Kastelein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Kastelein. The network helps show where J. Kastelein may publish in the future.

Co-authorship network of co-authors of J. Kastelein

This figure shows the co-authorship network connecting the top 25 collaborators of J. Kastelein. A scholar is included among the top collaborators of J. Kastelein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Kastelein. J. Kastelein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nicholls, Stephen C., Adam Nelson, Marc Ditmarsch, et al.. (2025). † Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia. Journal of clinical lipidology. 19(3). e91–e91. 1 indexed citations
2.
Hsieh, Andrew, et al.. (2024). †Obicetrapib Demonstrates Significant Reductions Of Lp(a) On Top Of High-intensity Statins. Journal of clinical lipidology. 18(4). e563–e564. 1 indexed citations
3.
Kastelein, J., Marc Ditmarsch, Andrew Hsieh, Mary R. Dicklin, & Michael Davidson. (2024). Obicetrapib does not accumulate in adipose tissue: Results from studies in man and non-human primates. Atherosclerosis. 395. 118209–118209. 1 indexed citations
4.
Yang, Xiaohong, et al.. (2024). Obicetrapib demonstrates significant reductions of Lp(a) on top of high-intensity statins. Atherosclerosis. 395. 118412–118412. 2 indexed citations
5.
Rosenson, Robert S., Frederick J. Raal, Laurens F. Reeskamp, et al.. (2020). The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolemia Patients with Little to No Low-Density Lipoprotein Receptor Activity. Journal of clinical lipidology. 14(4). 552–552. 1 indexed citations
6.
Fraser, David A., Xiaoyu Wang, Marta Iruarrizaga‐Lejarreta, et al.. (2019). LBP-10-A structurally engineered fatty acid, icosabutate, rapidly normalises elevated plasma ALTand gamma-glutamyl transferase (GGT) concentrations in a study population at high risk of NAFLD/NASH. Journal of Hepatology. 70(1). e145–e146. 1 indexed citations
7.
8.
9.
Langslet, Gisle, Marjet J.A.M. Braamskamp, Brian W. McCrindle, et al.. (2014). EFFICACY AND SAFETY OF ROSUVASTATIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE CHARON STUDY. Journal of the American College of Cardiology. 63(12). A1288–A1288.
10.
11.
Arsenault, Benoît, S. Matthijs Boekholdt, G. Kees Hovingh, et al.. (2011). THE TRP719ARG VARIANT OF KIF6 AND CARDIOVASCULAR OUTCOMES IN STATIN-TREATED, CORONARY STABLE PATIENTS OF THE TNT AND IDEAL PROSPECTIVE STUDIES. Journal of the American College of Cardiology. 57(14). E1203–E1203. 1 indexed citations
12.
Harchaoui, Karim El, Marjolein Visser, J. Kastelein, Erik S.G. Stroes, & Geesje M. Dallinga‐Thie. (2009). Triglycerides and Cardiovascular Risk. Current Cardiology Reviews. 5(3). 216–222. 102 indexed citations
13.
Barter, Philip J. & J. Kastelein. (2006). Translating today's science into clinical practice. Atherosclerosis Supplements. 7(1). 1–2. 1 indexed citations
14.
Cohen, Emily, et al.. (2004). Clinical, Diagnostic, and Therapeutic Aspects of Familial Hypercholesterolemia. Seminars in Vascular Medicine. 4(1). 31–41. 30 indexed citations
15.
16.
Barter, Philip J., J. Kastelein, Alistair V.W. Nunn, & Richard Hobbs. (2003). High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis. 168(2). 195–211. 164 indexed citations
17.
Defesche, Joep C., et al.. (2001). Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. The Lancet. 357(9251). 165–168. 346 indexed citations
18.
Smilde, Tineke J., et al.. (2001). Measurement of atherosclerosis progression. The Lancet. 358(9278). 329–329. 1 indexed citations
19.
Kastelein, J., José M. Ordovás, Marianne E. Wittekoek, et al.. (1999). Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clinical Genetics. 56(4). 297–305. 46 indexed citations
20.
Rust, Stephan, Michael Walter, Harald Funke, et al.. (1998). Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nature Genetics. 20(1). 96–98. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin P. Bogsrud Breakdown of academic impact, for papers by Robert S. Rosenson Breakdown of academic impact, for papers by Adriana Branchi Breakdown of academic impact, for papers by Amanda J. Berberich Breakdown of academic impact, for papers by Angelique C.M. Jansen Breakdown of academic impact, for papers by Paul Ziajka Breakdown of academic impact, for papers by Tomáš Štulc Breakdown of academic impact, for papers by Joost Besseling Breakdown of academic impact, for papers by M van Linde-Sibenius Trip Breakdown of academic impact, for papers by C.D. Furberg
Rankless by CCL
2026